Genetics and genomics of ankylosing spondylitis
Gethin P. Thomas,
Matthew A. Brown,
Gethin P. Thomas
Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Qld, Australia.
Search for more papers by this authorMatthew A. Brown
Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Qld, Australia.
Search for more papers by this authorGethin P. Thomas,
Matthew A. Brown,
Gethin P. Thomas
Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Qld, Australia.
Search for more papers by this authorMatthew A. Brown
Diamantina Institute of Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, Qld, Australia.
Search for more papers by this authorMatthew A. Brown
Diamantina Institute of Cancer, Immunology and Metabolic MedicinePrincess Alexandra HospitalIpswich RoadWoolloongabba, Qld 4102, AustraliaTel.: +61 7 3240 2870Fax: +61 7 3240 5946e-mail: [email protected]
Abstract
Summary: Ankylosing spondylitis (AS) is a common, highly heritable arthropathy, the pathogenesis of which is poorly understood. The mechanism by which the main gene for the disease, HLA-B27, leads to AS is unknown. Genetic and genomic studies have demonstrated involvement of the interleukin-23 (IL-23) signaling pathway in AS, a finding which has stimulated much new research into the disease and has led to therapeutic trials. Several other genes and genetic regions, including further major histocompatibility complex (MHC) and non-MHC loci, have been shown to be involved in the disease, but it is not clear yet how they actually induce the condition. These findings have shown that there is a strong genetic overlap between AS and Crohn’s disease in particular, although there are also major differences in the genes involved in the two conditions, presumably explaining their different presentations. Genomic and proteomic studies are in an early phase but have potential both as diagnostic/prognostic tools and as a further hypothesis-free tool to investigate AS pathogenesis. Given the slow progress in studying the mechanism of association of HLA-B27 with AS, these may prove to be more fruitful approaches to investigating the pathogenesis of the disease.
References
- 1 Brown MA, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997; 40: 1823–1828.
- 2 Pedersen O, Svendsen A, Ejstrup L, Skytthe A, Harris J, Junker P. Heritability estimates on ankylosing spondylitis. Clin Exp Rheumatol 2006; 24: 463.
- 3 Brown MA, et al. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum 2003; 48: 2234–2239.
- 4 Hamersma J, et al. Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheum 2001; 44: 1396–1400.
- 5 Brophy S, et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheumatol 2004; 31: 1775–1778.
- 6 Rubin LA, et al. Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994; 37: 1212–1220.
- 7 Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987; 40: 1–14.
- 8 Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990; 46: 222–228.
- 9 Brown MA, Laval SH, Brophy S, Calin A. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Ann Rheum Dis 2000; 59: 883–886.
- 10 Taurog JD, et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359–2364.
- 11 MacLean IL, et al. HLA-B27 subtypes in the spondarthropathies. Clin Exp Immunol 1993; 91: 214–219.
- 12 Armas JB, et al. Susceptibility to ankylosing spondylitis is independent of the Bw4 and Bw6 epitopes of HLA-B27 alleles. Tissue Antigens 1999; 53: 237–443.
- 13 Lopez-Larrea C, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis. Evidence for new associations. Tissue Antigens 1995; 45: 169–176.
- 14 Gonzalez-Roces S, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49: 116–123.
- 15 Garcia F, Rognan D, Lamas JR, Marina A, Lopez de Castro JA. An HLA-B27 polymorphism (B*2710) that is critical for T-cell recognition has limited effects on peptide specificity. Tissue Antigens 1998; 51: 1–9.
- 16 Garcia-Fernandez S, et al. New insights regarding HLA-B27 diversity in the Asian population. Tissue Antigens 2001; 58: 259–262.
- 17 Tamouza R, et al. A new HLA-B*27 allele (B*2719) identified in a Lebanese patient affected with ankylosing spondylitis. Tissue Antigens 2001; 58: 30–33.
- 18 Olivieri I, D’Angelo S, Scarano E, Santospirito V, Padula A. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis. Arthritis Rheum 2007; 56: 2805–2807.
- 19 Cauli A, et al. A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403. Arthritis Rheum 2007; 56: 2807–2809.
- 20 Nasution AR, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997; 24: 1111–1114.
- 21 Lopez-Larrea C, et al. Characterization of B27 haplotypes by oligotyping and genomic sequencing in the Mexican Mestizo population with ankylosing spondylitis: juvenile and adult onset. Hum Immunol 1995; 43: 174–180.
- 22 Hou TY, Chen HC, Chen CH, Chang DM, Liu FC, Lai JH. Usefulness of human leucocyte antigen-B27 subtypes in predicting ankylosing spondylitis: Taiwan experience. Intern Med J 2007; 37: 749–752.
- 23 Liu Y, et al. Predominant association of HLA-B*2704 with ankylosing spondylitis in Chinese Han patients. Tissue Antigens 2009;DOI: 10.1111/j.1399-0039.2009.01379.x.
- 24 Brown MA, Jepson A, Young A, Whittle HC, Greenwood BM, Wordsworth BP. Ankylosing spondylitis in West Africans – evidence for a non-HLA-B27 protective effect. Ann Rheum Dis 1997; 56: 68–70.
- 25 Breur-Vriesendorp BS, De-Waal LP, Ivanyi P. Different linkage disequilibria of HLA-B27 subtypes and HLA-C locus alleles. Tissue Antigens 1988; 32: 74–77.
- 26 Martinez-Borra J, et al. HLA-B27 alone rather than B27-related class I haplotypes contributes to ankylosing spondylitis susceptibility. Hum Immunol 2000; 61: 131–139.
- 27 Tsuchiya N, et al. MICA allele typing of HLA-B27 positive Japanese patients with seronegative spondylarthropathies and healthy individuals: differential linkage disequilibrium with HLA-B27 subtypes. Arthritis Rheum 1998; 41: 68–73.
- 28 Diaz-Pena R, Blanco-Gelaz MA, Njobvu P, Lopez-Vazquez A, Suarez-Alvarez B, Lopez-Larrea C. Influence of HLA-B*5703 and HLA-B*1403 on susceptibility to spondyloarthropathies in the Zambian population. J Rheumatol 2008; 35: 2236–2240.
- 29 Lopez-Larrea C, et al. Association of ankylosing spondylitis with HLA-B*1403 in a West African population. Arthritis Rheum 2002; 46: 2968–2971.
- 30 Merino E, Montserrat V, Paradela A, Lopez de Castro JA. Two HLA-B14 subtypes (B*1402 and B*1403) differentially associated with ankylosing spondylitis differ substantially in peptide specificity but have limited peptide and T-cell epitope sharing with HLA-B27. J Biol Chem 2005; 280: 35868–35880.
- 31 Breban M, et al. T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats. J Immunol 1996; 156: 794–803.
- 32 Taurog JD, et al. Spondylarthritis in HLA-B27/human beta(2)-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum 2009; 60: 1977–1984.
- 33 Allen RL, O’Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-microglobulin-free heavy chain homodimer structure. J Immunol 1999; 162: 5045–5048.
- 34 Kollnberger S, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002; 46: 2972–2982.
- 35 Kollnberger S, et al. Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol 2007; 37: 1313–1322.
- 36 Chan AT, Kollnberger SD, Wedderburn LR, Bowness P. Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 2005; 52: 3586–3595.
- 37 Tran TM, et al. HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP. J Immunol 2004; 172: 5110–5119.
- 38 Turner MJ, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005; 175: 2438–2448.
- 39 Smith JA, Turner MJ, DeLay ML, Klenk EI, Sowders DP, Colbert RA. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-beta induction via X-box binding protein 1. Eur J Immunol 2008; 38: 1194–1203.
- 40 Colbert RA, et al. HLA-B27 misfolding activates the IL-23/IL-17 axis via the unfolded protein response in transgenic rats: evidence for a novel mechanism of inflammation. Arthritis Rheum 2007; 1283: S515.
- 41 Robinson WP, et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989; 32: 1135–1141.
- 42 Brown MA, et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom. Ann Rheum Dis 1996; 55: 268–270.
- 43 Wei JC, Tsai WC, Lin HS, Tsai CY, Chou CT. HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients. Rheumatology (Oxford) 2004; 43: 839–842.
- 44 Brown MA, et al. HLA Class I and II associations of ankylosing spondylitis. Arthritis Rheum 2009; 60(Suppl): S437.
- 45 Sims AM, et al. Non-B27 MHC associations of ankylosing spondylitis. Genes Immun 2007; 8: 115–123.
- 46 Nejentsev S, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007; 450: 887–892.
- 47 Howson JM, Walker NM, Clayton D, Todd JA. Confirmation of HLA class II independent type 1 diabetes associations in the major histocompatibility complex including HLA-B and HLA-A. Diabetes Obes Metab 2009; 11(Suppl.): 31–45.
- 48 WTCCC TASC. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007; 39: 1329–1337.
- 49 Australo-Anglo-American Spondyloarthritis Consortium (TASC). Genomewide association study of ankylosing spondylitis identifies multiple non-MHC susceptibility loci. Nat Genet 2009: in press.
- 50 Duerr RH, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461–1463.
- 51 Dubinsky MC, et al. IL-23 receptor (IL-23R) gene protects against pediatric Crohn’s disease. Inflamm Bowel Dis 2007; 13: 511–515.
- 52 Cargill M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273–390.
- 53 Rahman P, Inman RD, Maksymowych WP, Reeve JP, Peddle L, Gladman DD. Association of interleukin 23 receptor variants with psoriatic arthritis. J Rheumatol 2009; 36: 137–140.
- 54 Rueda B, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008; 67: 1451–1454.
- 55 Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58: 1020–1025.
- 56 Karaderi T, et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. Rheumatology (Oxford) 2009; 48: 386–389.
- 57 Davidson S, et al. ERAP1 but not IL23R is associated with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum 2009; 60: 3263–3268.
- 58 Sung IH, et al. IL-23R polymorphisms in patients with ankylosing spondylitis in Korea. J Rheumatol 2009; 36: 1003–1005.
- 59 Yamazaki K, Onouchi Y, Takazoe M, Kubo M, Nakamura Y, Hata A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn’s disease in Japanese patients. J Hum Genet 2007; 52: 575–583.
- 60 Barrett JC, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 2008; 40: 955–962.
- 61 Milner JD, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452: 773–776.
- 62 Awasthi A, et al. Cutting edge: IL-23 receptor GFP reporter mice reveal distinct populations of IL-17-producing cells. J Immunol 2009; 182: 5904–5908.
- 63 Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58: 2307–2317.
- 64 Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007; 74: 304–305.
- 65 Kauffman CL, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123: 1037–1044.
- 66 Krueger GG, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580–592.
- 67 Mannon PJ, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med 2004; 351: 2069–2079.
- 68 Maksymowych WP, Inman RD, Gladman DD, Reeve JP, Pope A, Rahman P. Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum 2009; 60: 1317–1323.
- 69 Pimentel-Santos FM, et al. Association of IL23R and ERAP1 genes with ankylosing spondylitis in a Portuguese population. Clin Exp Rheumatol 2009; 27: 800–806.
- 70 Fung EY, et al. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun 2009; 10: 188–191.
- 71 Mehta AM, et al. Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer 2009; 48: 410–418.
- 72 Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother 2008; 57: 197–206.
- 73 Mehta AM, et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes Chromosomes Cancer 2007; 46: 577–586.
- 74 Cui X, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002; 110: 515–526.
- 75 Cui X, Rouhani FN, Hawari F, Levine SJ. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003; 171: 6814–6819.
- 76 Cui X, Rouhani FN, Hawari F, Levine SJ. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem 2003; 278: 28677–28685.
- 77 Chang SC, Momburg F, Bhutani N, Goldberg AL. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a “molecular ruler” mechanism. Proc Natl Acad Sci USA 2005; 102: 17107–17112.
- 78 Saveanu L, et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol 2005; 6: 689–697.
- 79 Blanchard N, et al. Immunodominant, protective response to the parasite Toxoplasma gondii requires antigen processing in the endoplasmic reticulum. Nat Immunol 2008; 9: 937–944.
- 80 Goto Y, Tanji H, Hattori A, Tsujimoto M. Glutamine-181 is crucial in the enzymatic activity and substrate specificity of human endoplasmic-reticulum aminopeptidase-1. Biochem J 2008; 416: 109–116.
- 81 Sims AM, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 2008; 67: 1305–1309.
- 82 McGarry F, Neilly J, Anderson N, Sturrock R, Field M. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford) 2001; 40: 1359–1364.
- 83 Van Der Paardt M, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford) 2002; 41: 1419–1423.
- 84 Maksymowych WP, et al. High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis Rheum 2003; 48: 2011–2018.
- 85 Timms AE, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004; 75: 587–595.
- 86 Dunne A, O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003: re3.
- 87 Kugathasan S, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008; 40: 1211–1215.
- 88 Dixon AL, et al. A genome-wide association study of global gene expression. Nat Genet 2007; 39: 1202–1207.
- 89 LeibundGut-Landmann S, et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007; 8: 630–638.
- 90 Pointon JJ, et al. Candidate genes for ankylosing spondylitis. Rheumatol 2009; 48: 82.
- 91 Zhernakova A, et al. Genetic analysis of innate immunity in Crohn’s disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet 2008; 82: 1202–1210.
- 92 Brown MA, et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis Rheum 1998; 41: 588–595.
- 93 Laval SH, et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. Am J Hum Genet 2001; 68: 918–926.
- 94 Miceli-Richard C, et al. Significant linkage to spondyloarthropathy on 9q31–34. Hum Mol Genet 2004; 13: 1641–1648.
- 95 Carter KW, et al. Combined analysis of three whole genome linkage scans for ankylosing spondylitis. Rheumatology (Oxford) 2007; 46: 763–771.
- 96 Yamazaki K, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn’s disease. Hum Mol Genet 2005; 14: 3499–3506.
- 97 Pappu BP, et al. TL1A-DR3 interaction regulates Th17 cell function and Th17-mediated autoimmune disease. J Exp Med 2008; 205: 1049–1062.
- 98 Takedatsu H, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 2008; 135: 552–567.
- 99 Bull MJ, et al. The death receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J Exp Med 2008; 205: 2457–2464.
- 100 Harvey D, et al. Analysis of killer immunoglobulin-like receptor (KIR) genes in ankylosing spondylitis. Ann Rheum Dis 2009; 68: 595–598.
- 101 Rihl M, et al. Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy. Ann Rheum Dis 2004; 63: 498–507.
- 102 Gu J, et al. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol 2002; 29: 2159–2164.
- 103 Rihl M, et al. Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. Arthritis Rheum 2008; 58: 3430–3435.
- 104 Laukens D, et al. Altered gut transcriptome in spondyloarthropathy. Ann Rheum Dis 2006; 65: 1293–1300.
- 105 Batliwalla FM, et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005; 11: 21–29.
- 106 Gu J, et al. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology 2002; 41: 759–766.
- 107 Smith JA, Barnes MD, Hong D, Delay ML, Inman RD, Colbert RA. Gene expression analysis of macrophages derived from ankylosing spondylitis patients reveals interferon-gamma dysregulation. Arthritis Rheum 2008; 58: 1640–1649.
- 108 Haroon N, et al. From gene expression to serum proteins: biomarker discovery in ankylosing spondylitis. Ann Rheum Dis 2009;DOI: ard.2008.102277v1.
- 109 Duan R, Leo P, Bradbury L, Brown M, Thomas G. Gene expression profiling reveals a down-regulation in immune-associated genes in AS patients. Ann Rheum Dis 2009;DOI: ard.2009.111690v1.
- 110 Batliwalla FM, et al. Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun 2005; 6: 388–397.
- 111 Bovin LF, et al. Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor. Immunol Lett 2004; 93: 217–226.
- 112 Nikpour M, Dempsey AA, Urowitz MB, Gladman DD, Barnes DA. Association of a gene expression profile from whole blood with disease activity in systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1069–1075.
- 113 Nzeusseu Toukap A, et al. Identification of distinct gene expression profiles in the synovium of patients with systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1579–1588.
- 114 Baechler EC, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610–2615.
- 115 O’Kane M, et al. Increased expression of the orphan nuclear receptor NURR1 in psoriasis and modulation following TNF-α inhibition. J Invest Dermatol 2007; 128: 300–310.
- 116 Satoh J, et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis 2005; 18: 537–550.
- 117 McEvoy AN, et al. Activation of nuclear orphan receptor NURR1 transcription by NF-κB and cyclic adenosine 5′-monophosphate response element-binding protein in rheumatoid arthritis synovial tissue. J Immunol 2002; 168: 2979–2987.
- 118 Plenge RM, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39: 1477–1482.
- 119 Nair RP, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-[kappa]B pathways. Nat Genet 2009; 41: 199–204.
- 120 Graham RR, et al. Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 2008; 40: 1059–1061.
- 121 Musone SL, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008; 40: 1062–1064.
- 122 Berthelot JM, Glemarec J, Guillot P, Laborie Y, Maugars Y. New pathogenic hypotheses for spondyloarthropathies. Joint Bone Spine 2002; 69: 114–122.
- 123 Carter JD, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009; 60: 1311–1316.
- 124 Pöllänen R, Sillat T, Pajarinen J, Levón J, Kaivosoja E, Konttinen YT. Microbial antigens mediate HLA-B27 diseases via TLRs. J Autoimmun 2009; 32: 172–177.
- 125 Rashid T, Ebringer A. Ankylosing spondylitis is linked to Klebsiella—the evidence. Clin Rheumatol 2007; 26: 858–864.
- 126 Yang XO, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity 2008; 28: 29–39.
- 127 Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Sem Immunol 2007; 19: 377–382.
- 128 Curtis MM, Way SS. Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009; 126: 177–185.
- 129 Inman RD. Mechanisms of disease: infection and spondyloarthritis. Nat Clin Pract Rheum 2006; 2: 163–169.
- 130 Toonen EJM, et al. Gene expression profiling in rheumatoid arthritis: current concepts and future directions. Ann Rheum Dis 2008; 67: 1663–1669.
- 131 Chang X, et al. Identification of proteins with increased expression in rheumatoid arthritis synovial tissues. J Rheumatol 2009; 36: 872–880.
- 132 Tilleman K, et al. Chronically inflamed synovium from spondyloarthropathy and rheumatoid arthritis investigated by protein expression profiling followed by tandem mass spectrometry. Proteomics 2005; 5: 2247–2257.
- 133 Kruithof E, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005; 52: 3898–3909.
- 134 Kruithof E, et al. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum 2006; 54: 1795–1804.
- 135 Liu W, Li X, Ding F, Li Y. Using SELDI-TOF MS to identify serum biomarkers of rheumatoid arthritis. Scand J Rheumatol 2008; 37: 94–102.
- 136 De Seny D, et al. Monomeric calgranulins measured by SELDI-TOF mass spectrometry and calprotectin measured by ELISA as biomarkers in arthritis. Clin Chem 2008; 54: 1066–1075.
- 137 Steinbrich-Zollner M, et al. From transcriptome to cytome: integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases. Cytometry A 2008; 73: 333–340.
- 138 Hueber W, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66: 712–719.
- 139 Vandooren B, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. Arthritis Rheum 2009; 60: 966–975.
- 140 Baeten D, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005; 7: R359–R369.
- 141 Wright CA, et al. Ankylosing spondylitis monocytes show upregulation of proteins involved in inflammation and the ubiquitin proteasome pathway. Ann Rheum Dis 2009; 68: 1626–1632.
- 142 Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment. Arthritis Res Ther 2008; 10: R125.
- 143 Romero-Sánchez C, et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008; 27: 1429–1435.
- 144 Vandooren B, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004; 50: 2942–2953.
- 145 Visvanathan S, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67: 511–517.
- 146 Woo J-H, Lee H-J, Sung I-H, Kim T-H. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007; 34: 1753–1759.
- 147 Briot K, et al. Effects of etanercept on serum biochemical markers of cartilage metabolism in patients with spondyloarthropathy. J Rheumatol 2008; 35: 310–314.
- 148 Uderhardt S, et al. Blockade of Dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 2009;DOI: ard.2008.102046v2.
- 149 Diarra D, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007; 13: 156–163.
- 150 Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005; 115: 1571–1579.
- 151 Toussirot E, Nguyen NU, Dumoulin G, Regnard J, Wendling D. Insulin-like growth factor-I and insulin-like growth factor binding protein-3 serum levels in ankylosing spondylitis. Rheumatology 1998; 37: 1172–1176.
- 152 Vandooren B, Cantaert T, Noordenbos T, Tak PP, Baeten D. The abundant synovial expression of the RANK/RANKL/osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum 2008; 58: 718–729.
- 153 Walsh NC, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009; 24: 1572–1585.
- 154 Lopez-Larrea C, et al. Contribution of KIR3DL1/3DS1 to ankylosing spondylitis in human leukocyte antigen-B27 Caucasian populations. Arthritis Res Ther 2006; 8: R101.
- 155 Jiao YL, et al. Polymorphisms of KIRs gene and HLA-C alleles in patients with ankylosing spondylitis: possible association with susceptibility to the disease. J Clin Immunol 2008; 28: 343–349.
- 156 Diaz-Pena R, et al. Activating KIR genes are associated with ankylosing spondylitis in Asian populations. Hum Immunol 2008; 69: 437–442.
Citing Literature
